The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allendorf, D. J.
Right arrow Articles by Haribabu, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allendorf, D. J.
Right arrow Articles by Haribabu, B.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Lymphoma
The Journal of Immunology, 2005, 174: 7050-7056.
Copyright © 2005 by The American Association of Immunologists

C5a-Mediated Leukotriene B4-Amplified Neutrophil Chemotaxis Is Essential in Tumor Immunotherapy Facilitated by Anti-Tumor Monoclonal Antibody and {beta}-Glucan1

Daniel J. Allendorf*,{dagger}, Jun Yan2,*,{dagger}, Gordon D. Ross3,*,{ddagger},{dagger}, Richard D. Hansen*, Jarek T. Baran4,*, Krishnaprasad Subbarao5,*, Li Wang* and Bodduluri Haribabu*,{dagger}

* Tumor Immunobiology Program of the James Graham Brown Cancer Center, Departments of{dagger} Microbiology and Immunology and{ddagger} Pathology and Laboratory Medicine, University of Louisville School of Medicine, Louisville, KY 40202

Intravenous and orally administered {beta}-glucans promote tumor regression and survival by priming granulocyte and macrophage C receptor 3 (CR3, iC3bR and CD11b/CD18) to trigger the cytotoxicity of tumor cells opsonized with iC3b via anti-tumor Abs. Despite evidence for priming of macrophage CR3 by oral {beta}-glucan in vivo, the current study in C57BL/6 and BALB/c mice showed that granulocytes were the essential killer cells in mAb- and oral {beta}-glucan-mediated tumor regression, because responses were absent in granulocyte-depleted mice. Among granulocytes, neutrophils were the major effector cells, because tumor regression did not occur when C5a-dependent chemotaxis was blocked with a C5aR antagonist, whereas tumor regression was normal in C3aR–/– mice. Neutrophil recruitment by C5a in vivo required amplification via leukotriene B4, because both C5a-mediated leukocyte recruitment into the peritoneal cavity and tumor regression were suppressed in leukotriene B4R-deficient (BLT-1–/–) mice.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
C. Salvador, B. Li, R. Hansen, D. E. Cramer, M. Kong, and J. Yan
Yeast-Derived {beta}-Glucan Augments the Therapeutic Efficacy Mediated by Anti-Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft Models
Clin. Cancer Res., February 15, 2008; 14(4): 1239 - 1247.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Li, D. J. Allendorf, R. Hansen, J. Marroquin, D. E. Cramer, C. L. Harris, and J. Yan
Combined Yeast {beta}-Glucan and Antitumor Monoclonal Antibody Therapy Requires C5a-Mediated Neutrophil Chemotaxis via Regulation of Decay-Accelerating Factor CD55
Cancer Res., August 1, 2007; 67(15): 7421 - 7430.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Li, D. J. Allendorf, R. Hansen, J. Marroquin, C. Ding, D. E. Cramer, and J. Yan
Yeast beta-Glucan Amplifies Phagocyte Killing of iC3b-Opsonized Tumor Cells via Complement Receptor 3-Syk-Phosphatidylinositol 3-Kinase Pathway
J. Immunol., August 1, 2006; 177(3): 1661 - 1669.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
N. D. Kim, R. C. Chou, E. Seung, A. M. Tager, and A. D. Luster
A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis
J. Exp. Med., April 17, 2006; 203(4): 829 - 835.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
Y. Kawasaki, M. Tanji, K. Takano, Y. Fukuda, M. Isome, R. Nozawa, H. Suzuki, and M. Hosoya
The leukotriene B4 receptor antagonist ONO-4057 inhibits mesangioproliferative changes in anti-Thy-1 nephritis
Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2697 - 2703.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.